CreatorsPublishersAdvertisers
View more in
Cancer

Dr. Anderson on Updated KarMMa Data With Ide-Cel in Multiple Myeloma

onclive.com
 2021-09-10

Larry Anderson, MD, PhD, discusses outcomes with idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma, as demonstrated in the phase 2 KarMMa trial. Larry Anderson, MD, PhD, associate professor in the Department of Internal Medicine of the Division of Hematology/Oncology, at Harold C. Simmons Comprehensive Cancer Center of UT Southwestern Medical Center, discusses outcomes with idecabtagene vicleucel (ide-cel, Abecma) in patients with relapsed/refractory multiple myeloma, as demonstrated in the phase 2 KarMMa trial (NCT03361748).

www.onclive.com

Comments / 0

Comments / 0